MX2017011838A - Composiciones y metodos para tratar carcinoma hepatocelular. - Google Patents
Composiciones y metodos para tratar carcinoma hepatocelular.Info
- Publication number
- MX2017011838A MX2017011838A MX2017011838A MX2017011838A MX2017011838A MX 2017011838 A MX2017011838 A MX 2017011838A MX 2017011838 A MX2017011838 A MX 2017011838A MX 2017011838 A MX2017011838 A MX 2017011838A MX 2017011838 A MX2017011838 A MX 2017011838A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- hepatocellular carcinoma
- compositions
- treating hepatocellular
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se proporcionan en la presente composiciones y métodos para tratar, mejorar, o prevenir carcinoma hepatocelular en pacientes. En particular, la invención se refiere a métodos para tratar, mejorar, o prevenir carcinoma hepatocelular en un paciente, que comprende la administración al paciente de 6-metoxietilamino-numon afida sola o en combinación con sorafenib.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562135435P | 2015-03-19 | 2015-03-19 | |
PCT/US2016/023212 WO2016149647A1 (en) | 2015-03-19 | 2016-03-18 | Compositions and methods for treating hepatocellular carcinoma |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017011838A true MX2017011838A (es) | 2018-06-06 |
Family
ID=56919582
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017011838A MX2017011838A (es) | 2015-03-19 | 2016-03-18 | Composiciones y metodos para tratar carcinoma hepatocelular. |
Country Status (7)
Country | Link |
---|---|
US (2) | US20180110743A1 (es) |
EP (1) | EP3270919A4 (es) |
JP (1) | JP2018508546A (es) |
AU (1) | AU2016232775A1 (es) |
CA (1) | CA2979843A1 (es) |
MX (1) | MX2017011838A (es) |
WO (1) | WO2016149647A1 (es) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5341081B2 (ja) * | 2007-07-25 | 2013-11-13 | アルマ マーテル ステューディオラム − ウニヴェルスィタ ディ ボローニャ | 肝細胞癌処置用医薬組成物および医薬キット |
JP6205373B2 (ja) * | 2012-02-03 | 2017-09-27 | ザ・ジョンズ・ホプキンス・ユニバーシティ | Ndga誘導体およびソラフェニブを含む組成物、ならびにがんの処置におけるこれらの使用 |
CN104257655B (zh) * | 2014-08-31 | 2016-06-22 | 浙江大学 | 化合物mean在制备抑制hcv复制的药物中的用途 |
-
2016
- 2016-03-18 MX MX2017011838A patent/MX2017011838A/es unknown
- 2016-03-18 CA CA2979843A patent/CA2979843A1/en not_active Abandoned
- 2016-03-18 WO PCT/US2016/023212 patent/WO2016149647A1/en active Application Filing
- 2016-03-18 AU AU2016232775A patent/AU2016232775A1/en not_active Abandoned
- 2016-03-18 US US15/559,327 patent/US20180110743A1/en not_active Abandoned
- 2016-03-18 EP EP16765848.3A patent/EP3270919A4/en not_active Withdrawn
- 2016-03-18 JP JP2017549005A patent/JP2018508546A/ja active Pending
-
2019
- 2019-07-18 US US16/515,844 patent/US20190374485A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2018508546A (ja) | 2018-03-29 |
AU2016232775A1 (en) | 2017-10-12 |
US20190374485A1 (en) | 2019-12-12 |
CA2979843A1 (en) | 2016-09-22 |
EP3270919A1 (en) | 2018-01-24 |
WO2016149647A1 (en) | 2016-09-22 |
US20180110743A1 (en) | 2018-04-26 |
EP3270919A4 (en) | 2018-10-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2018002990A (es) | Uso de la akkermansia pasteurizada para tratar trastornos metabolicos. | |
MY187540A (en) | Compounds active towards bromodomains | |
WO2019006005A3 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MELANOMA | |
MX2023000796A (es) | Composicion farmaceutica, metodos para tratamiento y sus usos. | |
MX370792B (es) | Composiciones para usarse en el tratamiento de cáncer. | |
MX2017005134A (es) | Tratamiento del cáncer con inmunoestimuladores. | |
MX2017015012A (es) | Formulaciones tópicas y orales que comprenden taurina y magnesio para la prevención y el tratamiento del acné. | |
PH12016502352A1 (en) | Pharmaceutical composition | |
MX2015014599A (es) | Terapia de combinacion que comprende un inhibidor de tor cinasa y un analogo de citidina para tracar cancer. | |
TW201613578A (en) | Pharmaceutical combinations | |
MX2017002489A (es) | Agentes terapeuticos humanos. | |
PH12016502233A1 (en) | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine | |
WO2014071168A3 (en) | Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients | |
MX2018014129A (es) | Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato. | |
PH12016502236A1 (en) | (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine | |
MX2015013755A (es) | Formulacion farmaceutica para uso en el tratamiento y/o prevencion de restenosis. | |
MX2017004723A (es) | Composicion farmaceutica para usarse en el tratamiento o la prevencion de deficiencias de vitaminas y minerales en pacientes que han sido sometidos a cirugia de derivacion gastrica. | |
MX2017013666A (es) | Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer. | |
MY198753A (en) | Treatment of androgen deprivation therapy associated symptoms | |
MX2020002585A (es) | Inhibidor de hdac combinado con un modulador del punto de control inmunitario para la terapia contra el cancer. | |
MX2018004532A (es) | Combinacion de trazodona y gabapentina para el tratamiento de dolor. | |
MX2017011838A (es) | Composiciones y metodos para tratar carcinoma hepatocelular. | |
MX2016001177A (es) | Tratamiento de esclerosis multiple con la combinacion de laquinimod y flupirtina. | |
MX2017013668A (es) | Terapia de combinacion de agente anti-fuctactico y agente anti-cancer y composiciones para el tratamiento de cancer. | |
MX2017014463A (es) | Cabazitaxel y su uso para tratar cancer. |